Welcome to our dedicated page for Sensus Healthcare news (Ticker: SRTS), a resource for investors and traders seeking the latest updates and insights on Sensus Healthcare stock.
Overview of Sensus Healthcare Inc.
Sensus Healthcare Inc. (Nasdaq: SRTS) is a specialized medical device company dedicated to advancing the field of non-invasive treatments for both oncological and non-oncological skin conditions. Headquartered in Boca Raton, Florida, the company has carved a niche in the healthcare industry through its proprietary superficial radiation therapy (SRT) technology. This innovative, low-energy X-ray radiation technology is the result of over a decade of rigorous research and development, enabling safe, effective, and cost-efficient treatment of conditions such as non-melanoma skin cancers (including basal and squamous cell carcinomas) and keloids.
Core Technology and Product Portfolio
At the heart of Sensus Healthcare's offerings is its proprietary SRT technology, which has been seamlessly integrated into its flagship devices, the SRT-100™ and SRT-100 Vision™. These devices are engineered to deliver precise, localized radiation therapy, making them ideal for outpatient settings. The company's products are designed to provide an alternative to surgical interventions, offering patients a painless, non-invasive treatment option with minimal downtime. Additionally, Sensus supports its customers through a comprehensive Sentinel Service Program, ensuring optimal device performance and customer satisfaction.
Market Applications and Value Proposition
Sensus Healthcare's devices address critical needs in dermatology and oncology, particularly in the treatment of non-melanoma skin cancers, which are among the most common forms of cancer globally. The company's technology also provides a unique solution for treating keloids, a condition often resistant to traditional therapies. By focusing on non-invasive, cost-effective, and patient-friendly treatment options, Sensus Healthcare appeals to a broad spectrum of healthcare providers, including dermatologists, oncologists, and hospital outpatient departments.
Industry Context and Competitive Landscape
The medical device industry is characterized by rapid technological advancements and a growing emphasis on non-invasive treatment modalities. Sensus Healthcare operates within this dynamic environment, competing with companies offering surgical, laser-based, or alternative radiotherapy solutions. Its differentiation lies in the proprietary nature of its SRT technology, which combines clinical efficacy with patient comfort. The company's commitment to research and development further strengthens its position, enabling it to address evolving market demands and maintain a competitive edge.
Revenue Model and Geographic Focus
Sensus Healthcare primarily generates revenue through the direct sale of its devices, complemented by service programs and potential licensing opportunities. The company's customer base is predominantly located in the United States, though its technology has global applicability, given the universal prevalence of the conditions it addresses.
Conclusion
Sensus Healthcare Inc. exemplifies innovation in the medical device industry, leveraging its proprietary SRT technology to offer non-invasive, effective, and patient-centric solutions for skin conditions. With a strong focus on R&D and a well-defined market niche, the company is well-positioned to meet the growing demand for advanced treatment options in dermatology and oncology. Its commitment to improving patient outcomes underscores its significance in the healthcare sector.
On April 25, 2023, Sensus Healthcare, Inc. (SRTS) announced a conference call scheduled for May 3, 2023, at 4:30 PM ET to discuss first-quarter 2023 financial results. During this call, management will also provide a business update and discuss ongoing and upcoming milestones. Participants can pre-register for the call to receive a unique dial-in number, allowing them to bypass the operator. The live webcast will be accessible through the company’s website, with a replay available until June 3, 2023. Sensus Healthcare specializes in non-invasive treatments for oncological and non-oncological conditions, offering innovative devices for skin cancer and aesthetic procedures.
Sensus Healthcare (Nasdaq:SRTS) has launched Sensus Cloud, a groundbreaking cloud-based platform designed for asset and EMR management in healthcare. This platform allows healthcare providers to collect real-time data from medical devices, streamlining patient monitoring and treatment management.
Key features include an intuitive interface for tracking patient treatment history, device usage, and service details, alongside predictive analytics for proactive care management. The system ensures data security with multi-factor authentication and encryption, enhancing user and patient data protection. Sensus Healthcare will showcase this innovative platform at the American Academy of Dermatology Annual Meeting from March 17-19, 2023.
Sensus Healthcare reported a 65% increase in full-year revenues, totaling $44.5 million for 2022, driven by increased product demand. Fourth-quarter revenues reached $13.1 million, slightly up from $13.0 million year-over-year. However, net income fell to $2.8 million ($0.17 per share) compared to $5.3 million ($0.32 per share) in Q4 2021, largely due to rising manufacturing costs.
The company ended 2022 with $25.5 million in cash and no debt, with expectations of continued growth and a focus on expanding aesthetic product offerings in 2023.
Sensus Healthcare, Inc. (Nasdaq: SRTS) will hold a conference call on February 9, 2023, at 4:30 p.m. ET to discuss its financial results for Q4 and the full year 2022. The call will include a business update and insights on recent and upcoming milestones. Investors can access the call through a dial-in number or via a live webcast. A replay of the call will be available until March 9, 2023. Sensus specializes in non-invasive medical devices that utilize proprietary low-energy X-ray technology for treating oncological conditions, enhancing patient quality of life.
Sensus Healthcare (Nasdaq: SRTS) has announced key promotions and appointments within its management team to enhance growth and operational efficiency. Promoted to COO is Maggie Martinez, who has been with the company for nine years. Emiliano Sosa becomes CTO, focusing on engineering and technology expansion. Stephanie Tipton is now VP of Marketing, while Sean Delaney is appointed VP of Regulatory and Quality Assurance, and Wayne Lura becomes VP of Aesthetic Sales. These changes are part of Sensus' aggressive business strategy aimed at improving customer support and expanding market reach.
Sensus Healthcare, Inc. (SRTS) reports strong preliminary revenues for Q4 2022 expected to exceed $13 million and an estimated $44 million for the full year, marking 60% growth over 2021. The fourth quarter revenues will also include over $500,000 from the aesthetics segment. Profitability is expected for both the quarter and the year. Plans for 2023 include expanding the domestic sales force, increasing trade show presence, and geographic expansion in the EU and Latin America.
Sensus Healthcare (SRTS) reported a 64% increase in revenues to $9.0 million for Q3 2022, compared to $5.5 million in Q3 2021. Net income rose to $1.8 million or $0.11 per diluted share, up from $0.2 million or $0.01 per share a year earlier. The company exited Q3 with $37.6 million in cash and no debt. Adjusted EBITDA improved to $2.3 million from $0.5 million. Despite economic headwinds and Hurricane Ian's impact, Sensus expects continued growth and profitability for the fourth quarter.
Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company focused on non-invasive treatments, will hold a conference call on November 3, 2022, at 4:30 p.m. ET to discuss its Q3 2022 financial results. The call will include a business update and insights on recent and upcoming milestones. Interested participants can access the call via dial-in or through a live webcast. An archived replay will be available until December 3, 2022. Sensus specializes in superficial radiation therapy for treating non-melanoma skin cancers and keloids.
Sensus Healthcare announced the launch of its Silk™ hair removal system at the Fall Clinical Dermatology Conference in Las Vegas, running from October 20-23, 2022. This portable device features a 2000W diode laser with blended wavelengths, suitable for all skin types. The innovative system promises efficient energy distribution without disposable parts, reducing costs for both patients and practitioners. The Silk™ system is available in two modes: an 810nm single wavelength and a blend of four wavelengths for comprehensive treatment. CEO Joe Sardano emphasizes its efficacy and versatility.
On September 9, 2022, Sensus Healthcare (Nasdaq: SRTS) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, scheduled for September 12-14, 2022, in New York City. Management will deliver a company overview and conduct one-on-one meetings with investors. A webcast of the presentation will be accessible on-demand starting September 12, 2022, at 7:00 a.m. ET on Sensus Healthcare’s website. The company specializes in innovative, non-invasive treatments for various conditions, particularly using its proprietary superficial radiation therapy technology.
FAQ
What is the current stock price of Sensus Healthcare (SRTS)?
What is the market cap of Sensus Healthcare (SRTS)?
What does Sensus Healthcare Inc. do?
What conditions does Sensus Healthcare's technology treat?
How does Sensus Healthcare generate revenue?
What makes Sensus Healthcare's technology unique?
Who are the primary customers of Sensus Healthcare?
What is the SRT-100 Vision™ device?
What challenges does Sensus Healthcare face in its market?
Where is Sensus Healthcare based?
What is the Sentinel Service Program by Sensus Healthcare?
What is superficial radiation therapy (SRT)?
